June 23, 2011
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that
Alan W. Dunton
, M.D., formally joined Palatin's Board of Directors on
June 22, 2011
as an independent director and member of Palatin's Audit and Compensation Committees.
"Dr. Dunton brings Palatin both substantial drug development experience and clinical research experience," said
, Ph.D., Palatin's CEO. "He has played a key role in the development of more than 20 products to regulatory approval. We look forward to working with him as a member of our Board of Directors."
Dr. Dunton is president and principal of Danerius, LLC, a consulting company he founded in 2006. From
, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and as a managing director of Panacos from
. Previously he was the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc. and as President and Chief Operating Officer of Emisphere Technologies, Inc. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including President and Managing Director of The Janssen Research Foundation. Dr. Dunton is a member of the board of directors of the publicly-traded companies Targacept, Inc. and Oragenics, Inc.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company focused on developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at
SOURCE Palatin Technologies, Inc.